Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Rating of “Hold” from Analysts

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have been given an average recommendation of “Hold” by the five ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $14.00.

ATRA has been the topic of several recent analyst reports. Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and cut their price objective for the stock from $25.00 to $18.00 in a report on Friday, August 16th. Canaccord Genuity Group restated a “buy” rating and set a $13.00 price objective on shares of Atara Biotherapeutics in a report on Tuesday, August 13th. The Goldman Sachs Group cut their price objective on Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating on the stock in a report on Wednesday, July 17th. Finally, HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a report on Wednesday, August 21st.

Atara Biotherapeutics Trading Up 8.0 %

Shares of NASDAQ ATRA opened at $9.58 on Thursday. Atara Biotherapeutics has a twelve month low of $4.96 and a twelve month high of $39.50. The company has a market capitalization of $46.15 million, a price-to-earnings ratio of -0.18 and a beta of 0.50. The firm has a 50-day moving average of $8.12 and a two-hundred day moving average of $10.76.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($3.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($1.54). The business had revenue of $28.64 million for the quarter, compared to the consensus estimate of $48.30 million. As a group, research analysts predict that Atara Biotherapeutics will post -12.09 earnings per share for the current year.

Hedge Funds Weigh In On Atara Biotherapeutics

A number of large investors have recently made changes to their positions in ATRA. Delap Wealth Advisory LLC acquired a new position in shares of Atara Biotherapeutics in the 1st quarter valued at about $29,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Atara Biotherapeutics in the 2nd quarter valued at about $53,000. Cubist Systematic Strategies LLC acquired a new position in shares of Atara Biotherapeutics in the 2nd quarter valued at about $79,000. BNP Paribas Financial Markets increased its holdings in shares of Atara Biotherapeutics by 29.3% in the 1st quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock valued at $266,000 after purchasing an additional 86,842 shares during the period. Finally, Acadian Asset Management LLC grew its stake in shares of Atara Biotherapeutics by 49.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,638,687 shares of the biotechnology company’s stock valued at $1,830,000 after buying an additional 873,133 shares in the last quarter. Institutional investors and hedge funds own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.